Vorinostat
A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4–4.4 months in earlier studies). Further brain tumor trials are planned in which vorinostat will be combined with other drugs.
Hypodiploid acute lymphoblastic leukemia
Hypodiploid acute lymphoblastic leukemia is the chromosome mutation of leukemic cells with 45 chromosomes or less. It has been determined that the prognosis of hypodiploid is much less than standard acute lymphoblastic leukemia. The lower the chromosome count, the lower the survival rate. In a study documented by the American Society of Hematology 17 of 27 patients relapsed, which indicates poor treatment responsiveness of hypodiploid ALL.
Hypodiploid is an unfavorable karyotypic feature in childhood ALL.